Evaluating the Effect of Mirtazapine on Anxiety in Parkinson's Disease Patients

Recruiting Phase 2 Interventional Study
Parkinson Disease Anxiety
Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 2
Study type
Interventional
Purpose
Treatment
Participants needed
64 (estimated)
Sponsor
Leila Dargahi. PharmD PhD · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
This study is a single-center, parallel and double-blind study in Movement Disorders Clinic of Shohadaye Tajrish Hospital. Patients, researchers (physicians, outcome assessors) and data analysts are blinded. After assessing the inclusion and exclusion criteria's, patients who assigned the informed consent form, are randomly divided into control and treatment groups.Patients in treatment or placebo…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Men and women over 17 years old * Patient with Parkinson's disease according to UKPDSBB criteria * Patient with mild/moderate Parkinson's disease according to Hoehn and Yahr Scale (HY score = 1-3) * Self-report or clinical diagnosis of anxiety * Patients who have signed inform…
Contacts

Leila Dargahi, PharmD/PhD

+989125069930

l.dargahi@sbmu.ac.ir

CONTACT